Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC
Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression ...
Jul 4, 2015
0
7